# Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

> **NCT02968901** · PHASE4 · TERMINATED · sponsor: **Actelion** · enrollment: 46 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** macitentan
- **DRUG:** tadalafil

## Key facts

- **NCT ID:** NCT02968901
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-01
- **Primary completion:** 2018-09-10
- **Final completion:** 2018-09-10
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968901, "Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02968901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*